Alvarius Pharmaceuticals

Phase 1 safety study announced for Q2 2024 — safety in humans plus addiction benefit evaluation; status unconfirmed

Why it matters: If Phase 1 started, it would be one of the first clinical trials of 5-MeO-DMT for addiction. However, no ClinicalTrials.gov registration found and no public confirmation of trial initiation. One patent filed.

Watch next: Phase 1 trial registration; clinical site disclosure; any press release confirming trial start

Actual: Jan 1, 2021

Founded in Dublin, Ireland; seed round ~EUR 2.7M (~$3.28M) from Re:Mind Capital (Christian Angermayer); total raised EUR 5.5M

Why it matters: Re:Mind Capital (Angermayer) is one of the most active psychedelic investors globally (also backed ATAI, Compass). EUR 5.5M total provides preclinical runway. Company collaborates with University College Dublin (UCD) — not UC Davis.

Actual: Jun 1, 2023

Preclinical data: 5-MeO-DMT reverses stimulant damage in 3D cerebral organoid models; genomic/proteomic profiling completed for stimulant, opioid, and alcohol addiction models

Why it matters: 3D cerebral organoids provide more physiologically relevant models than standard 2D cell cultures. Demonstrating structural reversal of stimulant-induced neuronal damage supports the neuroplasticity hypothesis for 5-MeO-DMT in addiction. Library of 5-MeO-DMT analogues also under investigation.